Is semaglutide safe during pregnancy?

The short answer is no. Semaglutide is contraindicated during pregnancy. Both the FDA-approved Ozempic label (section 8.1) and the Wegovy label carry the same risk summary: based on animal reproductive studies showing adverse fetal effects at doses below the human therapeutic range, semaglutide should not be used during pregnancy^[1]. There is no controlled human trial data on semaglutide in pregnancy, because all of the major clinical programmes excluded pregnant women from enrolment^[2].

This article explains what the label says, what the animal data showed, what happens at the clinical trial level (and why), and what the guidance is for people who are planning a pregnancy while on semaglutide.

Medical disclaimer: this article is for educational and journalistic purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any decision about semaglutide or any other prescription medicine.

What the prescribing information says

The FDA prescribing information for Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) and for Wegovy (semaglutide 2.4 mg) both state that semaglutide caused adverse fetal outcomes in animal reproduction studies at clinically relevant doses^[1]. In rat and rabbit studies conducted during organogenesis, semaglutide produced structural malformations, fetal growth restriction, and increased early pregnancy loss at exposures below those achieved at the maximum recommended human dose. The label notes that the relevance of these findings to humans is not fully established, but the risk is considered sufficient to classify pregnancy as a contraindication.

The label's clinical considerations section notes that pregnancy testing is recommended before starting semaglutide in women of reproductive potential. Because semaglutide has a long half-life (approximately one week), the recommended washout period before a planned conception is at least five half-lives, which translates to roughly five weeks after the last dose. The label does not specify a minimum interval, so this guidance should be discussed with a clinician.

For lactation (section 8.2), the label states that it is not known whether semaglutide is excreted in human breast milk. Animal studies showed semaglutide is present in rat milk at low levels, but the clinical significance for a breastfeeding infant is unknown. The label advises that the developmental and health benefits of breastfeeding should be considered alongside the risk to the infant and the mother's need for semaglutide.

Why pregnant women were excluded from the STEP and SUSTAIN trials

The STEP programme (the phase 3 obesity trials that established the 14.9% mean weight-loss figure in STEP-1) and the SUSTAIN programme (the diabetes cardiovascular outcomes and HbA1c trials) both listed current pregnancy, planned pregnancy, or breastfeeding as exclusion criteria. This is standard practice for phase 3 trials of any prescription medicine where preclinical safety signals indicate potential fetal harm^[2]. The result is that there is no randomised controlled evidence on semaglutide exposure during human pregnancy.

What does exist is post-marketing surveillance data and voluntary pregnancy registry reports, which are accumulated over time as patients inadvertently become pregnant while on a medicine or as clinicians report outcomes. As of the current writing, the volume of such data for semaglutide is limited. The label acknowledges the absence of adequate human pregnancy data and asks clinicians to report exposures through the appropriate pharmacovigilance systems.

Incidental exposure: what to do if pregnancy is discovered while on semaglutide

Because semaglutide is a once-weekly injection increasingly used in large populations, incidental exposure in early pregnancy is a clinical reality. The prescribing information does not carry a boxed warning specifically about pregnancy, but it does classify pregnancy as a contraindication. Clinical guidance generally recommends stopping semaglutide as soon as pregnancy is confirmed and informing the treating clinician immediately.

For people using semaglutide for type 2 diabetes, stopping mid-treatment means the underlying condition will need management through an alternative route. Insulin is the standard pharmacological option for glycaemic control in pregnancy and has a well-established safety record across decades of use. The semaglutide regulation pages note that semaglutide is prescription-only across all jurisdictions covered by this site; any switch in treatment requires a clinician's involvement.

For people using semaglutide for obesity management, the weight regain question is real but secondary to fetal safety. STEP-4 demonstrated that weight regain follows semaglutide discontinuation. That is a meaningful consideration for post-pregnancy planning, but not a reason to continue the medicine during pregnancy.

What we do not yet know

Several gaps remain in the evidence base. First, there is no published prospective registry data specific to semaglutide pregnancy exposure at scale. The available post-marketing data is accumulating but has not yet produced peer-reviewed outcome analyses large enough to characterise the risk precisely in humans. Second, the animal data for semaglutide comes from studies at doses that were clinically relevant, but animal-to-human extrapolation for reproductive toxicology is imperfect, and the magnitude of the human risk is genuinely uncertain. Third, there is no long-term follow-up data on children born after incidental first-trimester semaglutide exposure. Fourth, the optimal washout window before conception is a clinical estimate based on pharmacokinetics, not on an empirical pregnancy outcome dataset. And fifth, the question of whether semaglutide interacts with fertility at a mechanistic level has not been resolved: GLP-1 receptors are expressed in reproductive tissues, and the implications of receptor agonism in that context are not fully characterised.

The bottom line

Semaglutide is not safe to use during pregnancy based on current evidence. The FDA-approved prescribing information for Ozempic and Wegovy lists pregnancy as a contraindication, citing animal reproductive toxicity at clinically relevant exposures^[1]. No controlled human trial data exists because pregnant women were excluded from all phase 3 programmes^[2]. GLP-1 receptor agonists as a class share this contraindication^[3]. If you are on semaglutide and planning a pregnancy, the appropriate starting point is a conversation with your prescribing clinician about timing, washout, and alternative management for the underlying condition.